Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Liver Transplantation | 90 | 2022 | 1289 | 6.060 |
Why?
|
Immunosuppressive Agents | 29 | 2021 | 990 | 1.520 |
Why?
|
Islets of Langerhans Transplantation | 12 | 2021 | 240 | 1.510 |
Why?
|
Living Donors | 14 | 2022 | 343 | 1.490 |
Why?
|
Graft Rejection | 39 | 2014 | 1079 | 1.390 |
Why?
|
Hepatectomy | 12 | 2011 | 171 | 1.380 |
Why?
|
Liver Diseases | 11 | 2014 | 244 | 1.300 |
Why?
|
Tacrolimus | 19 | 2014 | 374 | 1.220 |
Why?
|
Portal Vein | 7 | 2018 | 119 | 1.120 |
Why?
|
Graft Survival | 31 | 2018 | 905 | 1.030 |
Why?
|
Tissue Donors | 12 | 2016 | 490 | 0.980 |
Why?
|
Postoperative Complications | 22 | 2022 | 2246 | 0.930 |
Why?
|
Liver Neoplasms | 12 | 2010 | 761 | 0.910 |
Why?
|
Kidney Transplantation | 24 | 2012 | 848 | 0.880 |
Why?
|
Tissue and Organ Procurement | 10 | 2022 | 336 | 0.860 |
Why?
|
Surgical Mesh | 4 | 2007 | 120 | 0.840 |
Why?
|
Pancreas Transplantation | 10 | 2006 | 104 | 0.830 |
Why?
|
Hepatic Artery | 7 | 2006 | 84 | 0.770 |
Why?
|
Organ Transplantation | 5 | 2017 | 273 | 0.770 |
Why?
|
Humans | 160 | 2022 | 87949 | 0.740 |
Why?
|
Islets of Langerhans | 6 | 2018 | 546 | 0.670 |
Why?
|
Liver, Artificial | 4 | 2002 | 7 | 0.650 |
Why?
|
Quality Improvement | 1 | 2022 | 433 | 0.650 |
Why?
|
Liver Failure | 4 | 2004 | 81 | 0.630 |
Why?
|
Abdominal Cavity | 2 | 2007 | 18 | 0.590 |
Why?
|
Adult | 75 | 2021 | 26131 | 0.590 |
Why?
|
Hernia, Inguinal | 2 | 2006 | 69 | 0.500 |
Why?
|
End Stage Liver Disease | 1 | 2015 | 67 | 0.480 |
Why?
|
Child | 42 | 2022 | 7065 | 0.480 |
Why?
|
Wounds, Gunshot | 2 | 2021 | 70 | 0.460 |
Why?
|
Muromonab-CD3 | 11 | 1998 | 69 | 0.440 |
Why?
|
Follow-Up Studies | 26 | 2018 | 3650 | 0.440 |
Why?
|
Insulin-Secreting Cells | 4 | 2019 | 403 | 0.430 |
Why?
|
Cyclosporine | 10 | 1998 | 239 | 0.430 |
Why?
|
Liver | 11 | 2022 | 1235 | 0.430 |
Why?
|
Sirolimus | 1 | 2014 | 172 | 0.430 |
Why?
|
Hepatocytes | 3 | 2002 | 127 | 0.420 |
Why?
|
Male | 74 | 2021 | 41697 | 0.420 |
Why?
|
Polyethylene Glycols | 2 | 2014 | 365 | 0.410 |
Why?
|
Female | 67 | 2022 | 45399 | 0.400 |
Why?
|
Prostheses and Implants | 2 | 2010 | 122 | 0.390 |
Why?
|
Intestines | 1 | 2014 | 413 | 0.390 |
Why?
|
Veterans | 1 | 2011 | 83 | 0.380 |
Why?
|
Diabetes Mellitus, Type 1 | 5 | 2021 | 561 | 0.370 |
Why?
|
T-Lymphocytes, Regulatory | 4 | 2014 | 300 | 0.360 |
Why?
|
Obesity | 2 | 2019 | 957 | 0.350 |
Why?
|
Stents | 4 | 2021 | 388 | 0.350 |
Why?
|
Duodenum | 3 | 2006 | 102 | 0.340 |
Why?
|
Lysine | 1 | 2010 | 149 | 0.340 |
Why?
|
Child, Preschool | 26 | 2016 | 3661 | 0.340 |
Why?
|
Middle Aged | 47 | 2021 | 25477 | 0.330 |
Why?
|
Time Factors | 28 | 2015 | 5284 | 0.330 |
Why?
|
Jaundice, Obstructive | 1 | 2008 | 10 | 0.320 |
Why?
|
Crohn Disease | 2 | 2014 | 747 | 0.310 |
Why?
|
Jejunum | 2 | 2006 | 80 | 0.310 |
Why?
|
Carcinoma, Hepatocellular | 6 | 2010 | 400 | 0.310 |
Why?
|
Liver Abscess | 1 | 2007 | 12 | 0.310 |
Why?
|
Fasting | 2 | 2018 | 163 | 0.310 |
Why?
|
Treatment Outcome | 20 | 2015 | 8104 | 0.310 |
Why?
|
Silicones | 1 | 2007 | 16 | 0.310 |
Why?
|
Hemangioma, Cavernous | 1 | 2008 | 69 | 0.300 |
Why?
|
Dimethylpolysiloxanes | 1 | 2007 | 15 | 0.300 |
Why?
|
Kidney | 5 | 2007 | 1140 | 0.300 |
Why?
|
Health Care Reform | 1 | 2008 | 86 | 0.300 |
Why?
|
Pyelonephritis, Xanthogranulomatous | 1 | 2007 | 2 | 0.300 |
Why?
|
Minocycline | 1 | 2007 | 15 | 0.300 |
Why?
|
Duodenal Diseases | 1 | 2007 | 23 | 0.290 |
Why?
|
Liver Failure, Acute | 1 | 2007 | 39 | 0.290 |
Why?
|
Patient Selection | 3 | 2020 | 685 | 0.290 |
Why?
|
Infant | 21 | 2015 | 3105 | 0.290 |
Why?
|
Diverticulum | 1 | 2007 | 45 | 0.280 |
Why?
|
Rectal Diseases | 1 | 2006 | 24 | 0.280 |
Why?
|
Bacterial Infections | 2 | 2005 | 184 | 0.280 |
Why?
|
Anti-Bacterial Agents | 3 | 2007 | 765 | 0.280 |
Why?
|
Portasystemic Shunt, Transjugular Intrahepatic | 4 | 2005 | 43 | 0.280 |
Why?
|
Adolescent | 30 | 2021 | 9111 | 0.270 |
Why?
|
Colonic Diseases | 1 | 2006 | 61 | 0.270 |
Why?
|
Tendons | 1 | 2006 | 44 | 0.270 |
Why?
|
Peritoneal Dialysis, Continuous Ambulatory | 1 | 2005 | 9 | 0.270 |
Why?
|
Foreign Bodies | 1 | 2006 | 64 | 0.260 |
Why?
|
Bioprosthesis | 1 | 2005 | 36 | 0.260 |
Why?
|
Antiviral Agents | 3 | 2022 | 513 | 0.260 |
Why?
|
Hepatic Veins | 2 | 2002 | 27 | 0.260 |
Why?
|
Anesthesia, Local | 1 | 2005 | 27 | 0.260 |
Why?
|
Ileostomy | 1 | 2005 | 30 | 0.260 |
Why?
|
Retrospective Studies | 30 | 2016 | 8780 | 0.260 |
Why?
|
Prosthesis-Related Infections | 1 | 2005 | 59 | 0.250 |
Why?
|
Graft Occlusion, Vascular | 3 | 2002 | 99 | 0.240 |
Why?
|
Transplantation, Homologous | 17 | 2013 | 1000 | 0.240 |
Why?
|
Prosthesis Implantation | 1 | 2005 | 126 | 0.240 |
Why?
|
Cyclic GMP | 1 | 2004 | 59 | 0.240 |
Why?
|
Catheterization | 1 | 2005 | 238 | 0.240 |
Why?
|
Pancreatitis, Chronic | 2 | 2015 | 54 | 0.230 |
Why?
|
Survival Rate | 15 | 2014 | 1877 | 0.230 |
Why?
|
Pancreas | 4 | 2018 | 243 | 0.230 |
Why?
|
Morbidity | 2 | 2022 | 147 | 0.230 |
Why?
|
Prospective Studies | 12 | 2021 | 4247 | 0.230 |
Why?
|
Bile Ducts | 2 | 2002 | 59 | 0.220 |
Why?
|
Extracorporeal Circulation | 1 | 2002 | 34 | 0.220 |
Why?
|
Ultrasonography, Doppler | 2 | 2002 | 85 | 0.220 |
Why?
|
Blood Loss, Surgical | 2 | 2001 | 115 | 0.220 |
Why?
|
Cholecystectomy | 1 | 2002 | 18 | 0.210 |
Why?
|
China | 4 | 2015 | 230 | 0.210 |
Why?
|
Cannabidiol | 1 | 2022 | 7 | 0.210 |
Why?
|
Pancreatectomy | 3 | 2018 | 155 | 0.210 |
Why?
|
Thrombosis | 4 | 2002 | 301 | 0.210 |
Why?
|
Rectus Abdominis | 2 | 2013 | 40 | 0.200 |
Why?
|
Abdominal Wall | 2 | 2013 | 30 | 0.200 |
Why?
|
Head Injuries, Penetrating | 1 | 2022 | 54 | 0.200 |
Why?
|
Mortality | 1 | 2022 | 150 | 0.200 |
Why?
|
Hepatitis C | 4 | 2012 | 219 | 0.190 |
Why?
|
Monitoring, Physiologic | 1 | 2002 | 265 | 0.190 |
Why?
|
Vascularized Composite Allotransplantation | 1 | 2021 | 14 | 0.190 |
Why?
|
Hypertension, Portal | 3 | 1998 | 47 | 0.190 |
Why?
|
Intraoperative Complications | 1 | 2002 | 188 | 0.190 |
Why?
|
Brain Injuries, Traumatic | 1 | 2022 | 87 | 0.180 |
Why?
|
Prognosis | 8 | 2018 | 3729 | 0.180 |
Why?
|
Perfusion | 2 | 2022 | 227 | 0.180 |
Why?
|
Policy | 1 | 2020 | 35 | 0.180 |
Why?
|
Biliary Tract Diseases | 2 | 1997 | 36 | 0.180 |
Why?
|
Host-Pathogen Interactions | 1 | 2022 | 233 | 0.170 |
Why?
|
Prisoners | 2 | 2011 | 44 | 0.170 |
Why?
|
Vena Cava, Inferior | 1 | 2021 | 144 | 0.170 |
Why?
|
Thrombectomy | 1 | 2021 | 168 | 0.170 |
Why?
|
Waiting Lists | 4 | 2007 | 188 | 0.170 |
Why?
|
Bile Duct Neoplasms | 2 | 2018 | 86 | 0.170 |
Why?
|
Hepatitis B | 5 | 2010 | 76 | 0.170 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2012 | 436 | 0.160 |
Why?
|
Biological Products | 1 | 2021 | 146 | 0.160 |
Why?
|
Reperfusion Injury | 2 | 1997 | 139 | 0.160 |
Why?
|
Informed Consent | 3 | 2011 | 272 | 0.160 |
Why?
|
Absorptiometry, Photon | 1 | 2019 | 100 | 0.160 |
Why?
|
Reoperation | 15 | 1999 | 605 | 0.160 |
Why?
|
Health Policy | 2 | 2011 | 184 | 0.160 |
Why?
|
Immunity, Innate | 1 | 2022 | 424 | 0.160 |
Why?
|
Laparoscopy | 1 | 2005 | 761 | 0.160 |
Why?
|
HIV Infections | 3 | 2012 | 827 | 0.160 |
Why?
|
Anastomosis, Surgical | 4 | 2006 | 268 | 0.160 |
Why?
|
Venous Thrombosis | 1 | 2021 | 249 | 0.160 |
Why?
|
Amino Acid Metabolism, Inborn Errors | 1 | 1998 | 11 | 0.160 |
Why?
|
Kidney Failure, Chronic | 3 | 2010 | 412 | 0.160 |
Why?
|
Urea | 1 | 1998 | 58 | 0.160 |
Why?
|
Ammonia | 1 | 1998 | 38 | 0.160 |
Why?
|
Cultural Characteristics | 2 | 2015 | 18 | 0.150 |
Why?
|
Donor Selection | 2 | 2018 | 73 | 0.150 |
Why?
|
Body Mass Index | 2 | 2019 | 765 | 0.150 |
Why?
|
Tomography, X-Ray Computed | 4 | 2008 | 2624 | 0.150 |
Why?
|
Gallbladder | 1 | 1997 | 30 | 0.150 |
Why?
|
Occlusive Dressings | 1 | 1996 | 7 | 0.140 |
Why?
|
Laparotomy | 2 | 2007 | 59 | 0.140 |
Why?
|
Chicago | 5 | 2021 | 1397 | 0.140 |
Why?
|
Polytetrafluoroethylene | 1 | 1996 | 74 | 0.140 |
Why?
|
Cyclosporins | 6 | 1991 | 58 | 0.140 |
Why?
|
Biliary Atresia | 4 | 1995 | 22 | 0.140 |
Why?
|
Cholangiocarcinoma | 3 | 2010 | 73 | 0.140 |
Why?
|
Liver Cirrhosis | 4 | 2010 | 302 | 0.130 |
Why?
|
Antibodies, Monoclonal | 5 | 2004 | 1397 | 0.130 |
Why?
|
Stomach | 2 | 2006 | 109 | 0.130 |
Why?
|
Tissue Preservation | 1 | 2015 | 15 | 0.130 |
Why?
|
Gift Giving | 1 | 2015 | 5 | 0.130 |
Why?
|
Social Control, Formal | 1 | 2015 | 12 | 0.130 |
Why?
|
Volition | 1 | 2015 | 15 | 0.130 |
Why?
|
Steroids | 1 | 1996 | 175 | 0.130 |
Why?
|
Pentanoic Acids | 1 | 2014 | 6 | 0.120 |
Why?
|
Cholangitis, Sclerosing | 2 | 2013 | 53 | 0.120 |
Why?
|
United States | 8 | 2021 | 6809 | 0.120 |
Why?
|
Biotin | 1 | 2014 | 45 | 0.120 |
Why?
|
Mixed Tumor, Malignant | 1 | 1994 | 3 | 0.120 |
Why?
|
International Agencies | 1 | 2014 | 34 | 0.120 |
Why?
|
Surface-Active Agents | 1 | 2014 | 60 | 0.120 |
Why?
|
Universities | 1 | 2015 | 146 | 0.120 |
Why?
|
Body Height | 1 | 2014 | 100 | 0.120 |
Why?
|
Carcinosarcoma | 1 | 1994 | 21 | 0.120 |
Why?
|
Colectomy | 3 | 2007 | 167 | 0.120 |
Why?
|
Mycophenolic Acid | 3 | 1998 | 88 | 0.120 |
Why?
|
Transplantation Immunology | 1 | 2014 | 82 | 0.110 |
Why?
|
Aged | 14 | 2016 | 18750 | 0.110 |
Why?
|
Health Behavior | 1 | 2015 | 183 | 0.110 |
Why?
|
Surgical Flaps | 2 | 2013 | 247 | 0.110 |
Why?
|
Tissue and Organ Harvesting | 2 | 2007 | 79 | 0.110 |
Why?
|
Heart Transplantation | 6 | 2008 | 717 | 0.110 |
Why?
|
Morphogenesis | 1 | 2014 | 205 | 0.110 |
Why?
|
Cadaver | 4 | 2002 | 185 | 0.110 |
Why?
|
Cryopreservation | 1 | 2013 | 73 | 0.110 |
Why?
|
Liver Function Tests | 3 | 1997 | 93 | 0.110 |
Why?
|
Monitoring, Immunologic | 1 | 2012 | 17 | 0.110 |
Why?
|
International Cooperation | 2 | 2011 | 123 | 0.100 |
Why?
|
Opportunistic Infections | 2 | 2010 | 59 | 0.100 |
Why?
|
Capital Punishment | 1 | 2011 | 3 | 0.100 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 2 | 1989 | 94 | 0.100 |
Why?
|
Animals | 13 | 2022 | 27028 | 0.100 |
Why?
|
Rats, Inbred Lew | 3 | 2010 | 191 | 0.100 |
Why?
|
Coinfection | 1 | 2012 | 58 | 0.100 |
Why?
|
Hepatoblastoma | 2 | 2010 | 12 | 0.100 |
Why?
|
Models, Theoretical | 1 | 2014 | 489 | 0.100 |
Why?
|
Immunologic Factors | 1 | 2013 | 170 | 0.100 |
Why?
|
Anti-Inflammatory Agents | 2 | 2013 | 342 | 0.100 |
Why?
|
Pancreatic Neoplasms | 2 | 1994 | 656 | 0.100 |
Why?
|
Liver Regeneration | 1 | 2011 | 36 | 0.100 |
Why?
|
Tumor Virus Infections | 2 | 2005 | 81 | 0.100 |
Why?
|
Death | 1 | 2011 | 80 | 0.100 |
Why?
|
Platelet Count | 1 | 2011 | 93 | 0.100 |
Why?
|
Hepatitis C, Chronic | 1 | 2012 | 126 | 0.090 |
Why?
|
Fascia | 1 | 2010 | 29 | 0.090 |
Why?
|
Hyperoxaluria | 1 | 2010 | 26 | 0.090 |
Why?
|
Hemangioendothelioma | 1 | 2010 | 9 | 0.090 |
Why?
|
Hepatic Encephalopathy | 2 | 2001 | 43 | 0.090 |
Why?
|
Survival Analysis | 8 | 2012 | 1539 | 0.090 |
Why?
|
Incidence | 6 | 2012 | 1580 | 0.090 |
Why?
|
Alginates | 1 | 2010 | 15 | 0.090 |
Why?
|
Capsules | 1 | 2010 | 38 | 0.090 |
Why?
|
Polylysine | 1 | 2010 | 34 | 0.090 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2015 | 520 | 0.090 |
Why?
|
Gene Expression Regulation | 1 | 2019 | 1956 | 0.090 |
Why?
|
Tumor Necrosis Factor-alpha | 5 | 1991 | 695 | 0.090 |
Why?
|
Costs and Cost Analysis | 3 | 2021 | 155 | 0.090 |
Why?
|
Transplantation Tolerance | 1 | 2011 | 134 | 0.090 |
Why?
|
Enterococcus | 2 | 2001 | 35 | 0.090 |
Why?
|
Antibodies | 4 | 2000 | 353 | 0.090 |
Why?
|
Young Adult | 6 | 2019 | 6151 | 0.090 |
Why?
|
Radiography | 3 | 2007 | 810 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 1939 | 0.090 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 1989 | 384 | 0.090 |
Why?
|
Resuscitation | 2 | 2022 | 103 | 0.090 |
Why?
|
Interferon-gamma | 1 | 2011 | 448 | 0.090 |
Why?
|
ABO Blood-Group System | 2 | 2008 | 59 | 0.080 |
Why?
|
Age Factors | 5 | 2019 | 1853 | 0.080 |
Why?
|
Drug Compounding | 1 | 2010 | 80 | 0.080 |
Why?
|
Neuroendocrine Tumors | 1 | 2010 | 108 | 0.080 |
Why?
|
Sensitivity and Specificity | 3 | 2019 | 2019 | 0.080 |
Why?
|
Sarcoma | 1 | 2010 | 220 | 0.080 |
Why?
|
Illinois | 2 | 2002 | 465 | 0.080 |
Why?
|
Organ Preservation | 3 | 2022 | 98 | 0.080 |
Why?
|
Chemoembolization, Therapeutic | 1 | 2008 | 37 | 0.080 |
Why?
|
Amikacin | 1 | 2007 | 5 | 0.080 |
Why?
|
Documentation | 1 | 2009 | 103 | 0.080 |
Why?
|
Blood Group Incompatibility | 1 | 2008 | 20 | 0.080 |
Why?
|
C-Peptide | 2 | 2018 | 179 | 0.080 |
Why?
|
Ciprofloxacin | 1 | 2007 | 29 | 0.080 |
Why?
|
Guanine | 1 | 2008 | 208 | 0.080 |
Why?
|
Kidney Diseases | 3 | 2005 | 318 | 0.080 |
Why?
|
Lymphoproliferative Disorders | 3 | 2001 | 111 | 0.080 |
Why?
|
Rats | 6 | 2010 | 4022 | 0.080 |
Why?
|
Body Weight | 2 | 2014 | 451 | 0.070 |
Why?
|
Biopsy | 5 | 1999 | 1181 | 0.070 |
Why?
|
Iliac Vein | 1 | 2007 | 30 | 0.070 |
Why?
|
Pseudomonas Infections | 1 | 2007 | 96 | 0.070 |
Why?
|
Creatinine | 5 | 1999 | 295 | 0.070 |
Why?
|
Iliac Artery | 1 | 2007 | 37 | 0.070 |
Why?
|
Health Care Rationing | 2 | 2004 | 83 | 0.070 |
Why?
|
Acne Vulgaris | 1 | 2007 | 35 | 0.070 |
Why?
|
Prednisone | 5 | 1998 | 258 | 0.070 |
Why?
|
Rare Diseases | 1 | 2007 | 63 | 0.070 |
Why?
|
Splenic Artery | 1 | 2006 | 11 | 0.070 |
Why?
|
Length of Stay | 3 | 2001 | 716 | 0.070 |
Why?
|
Aorta, Abdominal | 1 | 2006 | 59 | 0.070 |
Why?
|
Intestinal Perforation | 1 | 2006 | 35 | 0.070 |
Why?
|
Medical Oncology | 1 | 2010 | 374 | 0.070 |
Why?
|
Pressure | 1 | 2007 | 166 | 0.070 |
Why?
|
Ethics, Medical | 1 | 2009 | 308 | 0.070 |
Why?
|
Pseudomonas aeruginosa | 1 | 2007 | 197 | 0.070 |
Why?
|
Neoplasm Metastasis | 1 | 2010 | 1094 | 0.070 |
Why?
|
Risk Assessment | 2 | 2019 | 2274 | 0.070 |
Why?
|
Polypropylenes | 1 | 2005 | 23 | 0.070 |
Why?
|
Transplantation, Autologous | 2 | 2018 | 340 | 0.070 |
Why?
|
Anal Canal | 1 | 2006 | 89 | 0.070 |
Why?
|
Blood Glucose | 3 | 2018 | 839 | 0.070 |
Why?
|
Necrosis | 1 | 2006 | 208 | 0.070 |
Why?
|
Biopsy, Needle | 3 | 1998 | 235 | 0.070 |
Why?
|
Risk Factors | 10 | 2012 | 5405 | 0.070 |
Why?
|
Drug Resistance | 2 | 1996 | 232 | 0.070 |
Why?
|
Chronic Disease | 4 | 2008 | 942 | 0.060 |
Why?
|
Anesthesia, General | 1 | 2006 | 116 | 0.060 |
Why?
|
BK Virus | 1 | 2005 | 23 | 0.060 |
Why?
|
Polyomavirus Infections | 1 | 2005 | 28 | 0.060 |
Why?
|
Isoxazoles | 1 | 2005 | 77 | 0.060 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2013 | 1157 | 0.060 |
Why?
|
Disease Susceptibility | 1 | 2005 | 198 | 0.060 |
Why?
|
Acute Disease | 4 | 1999 | 838 | 0.060 |
Why?
|
Nephrectomy | 1 | 2007 | 292 | 0.060 |
Why?
|
Cohort Studies | 3 | 2018 | 2802 | 0.060 |
Why?
|
California | 3 | 1997 | 143 | 0.060 |
Why?
|
Mice | 4 | 2022 | 11619 | 0.060 |
Why?
|
Biocompatible Materials | 1 | 2005 | 196 | 0.060 |
Why?
|
Cell Separation | 1 | 2004 | 195 | 0.060 |
Why?
|
Membrane Proteins | 1 | 2010 | 1212 | 0.060 |
Why?
|
Surgical Procedures, Operative | 1 | 2005 | 190 | 0.060 |
Why?
|
Cell Culture Techniques | 1 | 2004 | 189 | 0.060 |
Why?
|
Hospitals, University | 3 | 1999 | 195 | 0.060 |
Why?
|
Thermodynamics | 1 | 2004 | 309 | 0.060 |
Why?
|
Canada | 2 | 2007 | 206 | 0.060 |
Why?
|
Decision Support Techniques | 1 | 2004 | 165 | 0.050 |
Why?
|
Organ Size | 2 | 2014 | 367 | 0.050 |
Why?
|
Pain, Postoperative | 1 | 2005 | 247 | 0.050 |
Why?
|
Temperature | 1 | 2004 | 400 | 0.050 |
Why?
|
Cell Line, Transformed | 1 | 2002 | 155 | 0.050 |
Why?
|
Adrenal Cortex Hormones | 2 | 1998 | 266 | 0.050 |
Why?
|
Virus Replication | 2 | 2022 | 321 | 0.050 |
Why?
|
Intracranial Pressure | 1 | 2002 | 81 | 0.050 |
Why?
|
Colorectal Neoplasms | 2 | 2000 | 956 | 0.050 |
Why?
|
Antilymphocyte Serum | 5 | 2004 | 71 | 0.050 |
Why?
|
Biomarkers, Tumor | 1 | 2010 | 1511 | 0.050 |
Why?
|
Regional Blood Flow | 1 | 2002 | 198 | 0.050 |
Why?
|
Bilirubin | 3 | 1999 | 130 | 0.050 |
Why?
|
A549 Cells | 1 | 2022 | 40 | 0.050 |
Why?
|
Iatrogenic Disease | 1 | 2002 | 69 | 0.050 |
Why?
|
Aged, 80 and over | 3 | 2013 | 6655 | 0.050 |
Why?
|
Vero Cells | 1 | 2022 | 101 | 0.050 |
Why?
|
Virus Internalization | 1 | 2022 | 39 | 0.050 |
Why?
|
Drug Administration Schedule | 4 | 1998 | 900 | 0.050 |
Why?
|
Constriction, Pathologic | 1 | 2002 | 216 | 0.050 |
Why?
|
Cardiotonic Agents | 1 | 2002 | 89 | 0.050 |
Why?
|
Insulin | 3 | 2018 | 1152 | 0.050 |
Why?
|
Cholecystectomy, Laparoscopic | 1 | 2002 | 51 | 0.050 |
Why?
|
Vancomycin Resistance | 1 | 2001 | 18 | 0.050 |
Why?
|
Respiratory Insufficiency | 2 | 2001 | 159 | 0.050 |
Why?
|
Endoplasmic Reticulum Stress | 1 | 2022 | 85 | 0.050 |
Why?
|
Gene Expression Regulation, Viral | 1 | 2022 | 90 | 0.050 |
Why?
|
Constriction | 1 | 2001 | 27 | 0.050 |
Why?
|
Interferons | 1 | 2022 | 134 | 0.050 |
Why?
|
Biological Availability | 2 | 1998 | 92 | 0.050 |
Why?
|
Bile | 2 | 2001 | 57 | 0.050 |
Why?
|
Endoribonucleases | 1 | 2022 | 92 | 0.050 |
Why?
|
Cerebrovascular Circulation | 1 | 2002 | 220 | 0.050 |
Why?
|
Severity of Illness Index | 1 | 2007 | 1827 | 0.050 |
Why?
|
Hepatitis, Autoimmune | 1 | 2001 | 20 | 0.050 |
Why?
|
Positive-Pressure Respiration | 1 | 2001 | 41 | 0.050 |
Why?
|
Foreign-Body Migration | 1 | 2001 | 38 | 0.050 |
Why?
|
Antimetabolites | 1 | 2000 | 24 | 0.050 |
Why?
|
Biliary Tract Neoplasms | 1 | 2000 | 33 | 0.050 |
Why?
|
Heart Rate | 1 | 2002 | 492 | 0.050 |
Why?
|
Neurosurgical Procedures | 1 | 2022 | 218 | 0.040 |
Why?
|
Immunotherapy | 2 | 1999 | 655 | 0.040 |
Why?
|
Respiratory Tract Diseases | 1 | 2000 | 45 | 0.040 |
Why?
|
Autoantibodies | 1 | 2001 | 267 | 0.040 |
Why?
|
Computed Tomography Angiography | 1 | 2021 | 135 | 0.040 |
Why?
|
Intraoperative Period | 2 | 1997 | 90 | 0.040 |
Why?
|
Transplantation, Heterologous | 1 | 2021 | 370 | 0.040 |
Why?
|
Hepatitis, Alcoholic | 1 | 1999 | 19 | 0.040 |
Why?
|
Fatal Outcome | 2 | 2010 | 295 | 0.040 |
Why?
|
Cell Transplantation | 1 | 1999 | 47 | 0.040 |
Why?
|
Mice, Nude | 1 | 2021 | 810 | 0.040 |
Why?
|
Program Evaluation | 1 | 2000 | 302 | 0.040 |
Why?
|
Blood Pressure | 1 | 2002 | 885 | 0.040 |
Why?
|
Emulsions | 1 | 1998 | 19 | 0.040 |
Why?
|
North America | 1 | 2018 | 184 | 0.040 |
Why?
|
Nutrition Surveys | 1 | 2019 | 111 | 0.040 |
Why?
|
Carbamoyl-Phosphate Synthase (Ammonia) | 1 | 1998 | 4 | 0.040 |
Why?
|
Ornithine Carbamoyltransferase Deficiency Disease | 1 | 1998 | 4 | 0.040 |
Why?
|
Cytokines | 1 | 2022 | 795 | 0.040 |
Why?
|
Citrulline | 1 | 1998 | 10 | 0.040 |
Why?
|
Communication Disorders | 1 | 1998 | 7 | 0.040 |
Why?
|
Diagnosis, Differential | 3 | 2010 | 1586 | 0.040 |
Why?
|
Anticoagulants | 1 | 2001 | 420 | 0.040 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2001 | 1347 | 0.040 |
Why?
|
Epithelial Cells | 1 | 2022 | 685 | 0.040 |
Why?
|
Alcoholism | 1 | 1999 | 174 | 0.040 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 1998 | 47 | 0.040 |
Why?
|
Microcephaly | 1 | 1998 | 76 | 0.040 |
Why?
|
Multivariate Analysis | 3 | 2010 | 994 | 0.040 |
Why?
|
Vancomycin | 1 | 1998 | 73 | 0.040 |
Why?
|
Glucose Tolerance Test | 1 | 2018 | 227 | 0.040 |
Why?
|
Coccidioidomycosis | 1 | 1997 | 7 | 0.040 |
Why?
|
Genetic Therapy | 1 | 1999 | 354 | 0.040 |
Why?
|
Dosage Forms | 1 | 1996 | 7 | 0.040 |
Why?
|
Double-Blind Method | 1 | 2021 | 1711 | 0.040 |
Why?
|
Intellectual Disability | 1 | 1998 | 189 | 0.030 |
Why?
|
Methylprednisolone | 1 | 1996 | 66 | 0.030 |
Why?
|
Syndrome | 1 | 1997 | 446 | 0.030 |
Why?
|
Cardiac Surgical Procedures | 1 | 2001 | 473 | 0.030 |
Why?
|
Herpesvirus 4, Human | 1 | 1996 | 119 | 0.030 |
Why?
|
Oxygen | 1 | 2001 | 741 | 0.030 |
Why?
|
Quality of Life | 3 | 1996 | 1638 | 0.030 |
Why?
|
Situs Inversus | 1 | 1995 | 15 | 0.030 |
Why?
|
Sex Factors | 1 | 2019 | 1059 | 0.030 |
Why?
|
Pancreatic Function Tests | 1 | 2015 | 7 | 0.030 |
Why?
|
Somatostatin-Secreting Cells | 1 | 2015 | 7 | 0.030 |
Why?
|
Public Opinion | 1 | 2015 | 42 | 0.030 |
Why?
|
Glucagon-Secreting Cells | 1 | 2015 | 25 | 0.030 |
Why?
|
Logistic Models | 1 | 2018 | 1200 | 0.030 |
Why?
|
Altruism | 1 | 2015 | 35 | 0.030 |
Why?
|
Hepatitis, Viral, Human | 2 | 1999 | 26 | 0.030 |
Why?
|
Administration, Oral | 1 | 1996 | 680 | 0.030 |
Why?
|
Carbocyanines | 1 | 2014 | 18 | 0.030 |
Why?
|
Succinimides | 1 | 2014 | 13 | 0.030 |
Why?
|
Streptavidin | 1 | 2014 | 14 | 0.030 |
Why?
|
Tissue Survival | 1 | 2014 | 13 | 0.030 |
Why?
|
Intestine, Small | 1 | 1996 | 303 | 0.030 |
Why?
|
Age of Onset | 1 | 2015 | 311 | 0.030 |
Why?
|
Tissue Culture Techniques | 1 | 2014 | 81 | 0.030 |
Why?
|
Feasibility Studies | 2 | 2011 | 769 | 0.030 |
Why?
|
Cell Communication | 1 | 2014 | 195 | 0.030 |
Why?
|
Celiac Plexus | 1 | 1993 | 3 | 0.030 |
Why?
|
Hepatitis B virus | 2 | 2008 | 44 | 0.030 |
Why?
|
Nerve Compression Syndromes | 1 | 1993 | 18 | 0.030 |
Why?
|
Leiomyosarcoma | 1 | 1994 | 43 | 0.030 |
Why?
|
Family | 1 | 1995 | 316 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 379 | 0.030 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2013 | 36 | 0.030 |
Why?
|
Pilot Projects | 2 | 2011 | 861 | 0.030 |
Why?
|
Swine | 1 | 2014 | 577 | 0.030 |
Why?
|
Cell Adhesion | 1 | 2014 | 425 | 0.030 |
Why?
|
Cell- and Tissue-Based Therapy | 1 | 2013 | 50 | 0.030 |
Why?
|
Hemorrhage | 2 | 2000 | 273 | 0.030 |
Why?
|
Recurrence | 4 | 1998 | 1168 | 0.030 |
Why?
|
C-Reactive Protein | 1 | 2013 | 193 | 0.030 |
Why?
|
Azathioprine | 3 | 1998 | 125 | 0.030 |
Why?
|
Abdomen, Acute | 1 | 2012 | 20 | 0.030 |
Why?
|
T-Lymphocytes | 2 | 1989 | 1209 | 0.030 |
Why?
|
Cholestasis | 1 | 1992 | 46 | 0.030 |
Why?
|
Academic Medical Centers | 1 | 1995 | 382 | 0.030 |
Why?
|
Medical Tourism | 1 | 2011 | 5 | 0.030 |
Why?
|
Immunoassay | 1 | 2012 | 92 | 0.030 |
Why?
|
CD3 Complex | 2 | 1989 | 134 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2013 | 170 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2013 | 202 | 0.030 |
Why?
|
Enzyme-Linked Immunospot Assay | 1 | 2011 | 8 | 0.030 |
Why?
|
Drainage | 3 | 1998 | 157 | 0.030 |
Why?
|
Immunity, Cellular | 1 | 2012 | 178 | 0.020 |
Why?
|
Inflammatory Bowel Diseases | 1 | 1998 | 564 | 0.020 |
Why?
|
Advisory Committees | 1 | 2011 | 88 | 0.020 |
Why?
|
Colitis, Ulcerative | 2 | 2013 | 723 | 0.020 |
Why?
|
Algorithms | 2 | 2014 | 1857 | 0.020 |
Why?
|
Hepacivirus | 1 | 2012 | 162 | 0.020 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2010 | 33 | 0.020 |
Why?
|
Drug Therapy, Combination | 3 | 1998 | 795 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 1998 | 743 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2010 | 66 | 0.020 |
Why?
|
Brain Death | 1 | 2011 | 72 | 0.020 |
Why?
|
alpha-Fetoproteins | 1 | 2010 | 45 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2015 | 1786 | 0.020 |
Why?
|
Chemoprevention | 1 | 2010 | 92 | 0.020 |
Why?
|
Hypertonic Solutions | 1 | 1990 | 17 | 0.020 |
Why?
|
Abdomen | 1 | 2010 | 121 | 0.020 |
Why?
|
Organ Preservation Solutions | 1 | 1990 | 29 | 0.020 |
Why?
|
Solutions | 1 | 1990 | 85 | 0.020 |
Why?
|
In Vitro Techniques | 1 | 2011 | 993 | 0.020 |
Why?
|
Adenocarcinoma | 2 | 1994 | 1182 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2014 | 1697 | 0.020 |
Why?
|
Blood Transfusion | 1 | 1990 | 164 | 0.020 |
Why?
|
Kidney Tubular Necrosis, Acute | 2 | 1999 | 9 | 0.020 |
Why?
|
Portasystemic Shunt, Surgical | 1 | 1989 | 12 | 0.020 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 1989 | 44 | 0.020 |
Why?
|
Portoenterostomy, Hepatic | 1 | 1988 | 3 | 0.020 |
Why?
|
Random Allocation | 1 | 1989 | 329 | 0.020 |
Why?
|
Rupture | 1 | 2008 | 62 | 0.020 |
Why?
|
Aspergillosis | 1 | 1988 | 41 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2010 | 858 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2010 | 856 | 0.020 |
Why?
|
Methylprednisolone Hemisuccinate | 2 | 1998 | 10 | 0.020 |
Why?
|
DNA, Viral | 1 | 2008 | 265 | 0.020 |
Why?
|
Infant, Newborn | 3 | 1998 | 2436 | 0.020 |
Why?
|
Cell Differentiation | 1 | 1994 | 1501 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2014 | 3169 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2013 | 1225 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2010 | 539 | 0.020 |
Why?
|
Rats, Inbred BUF | 3 | 1991 | 4 | 0.020 |
Why?
|
Los Angeles | 2 | 1996 | 28 | 0.020 |
Why?
|
Angiography | 1 | 2006 | 208 | 0.020 |
Why?
|
Crotonates | 1 | 2005 | 11 | 0.020 |
Why?
|
Toluidines | 1 | 2005 | 17 | 0.020 |
Why?
|
Combined Modality Therapy | 3 | 1995 | 1703 | 0.020 |
Why?
|
Hydroxybutyrates | 1 | 2005 | 27 | 0.020 |
Why?
|
Aniline Compounds | 1 | 2005 | 56 | 0.020 |
Why?
|
Nitriles | 1 | 2005 | 157 | 0.020 |
Why?
|
Receptors, Interleukin-2 | 1 | 2004 | 66 | 0.020 |
Why?
|
Esophageal and Gastric Varices | 2 | 1998 | 34 | 0.010 |
Why?
|
Urinary Bladder | 2 | 1996 | 246 | 0.010 |
Why?
|
Lymphocyte Depletion | 1 | 2004 | 97 | 0.010 |
Why?
|
Small-Area Analysis | 1 | 2003 | 8 | 0.010 |
Why?
|
Health Priorities | 1 | 2003 | 22 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 1989 | 1141 | 0.010 |
Why?
|
Geography | 1 | 2003 | 228 | 0.010 |
Why?
|
Neoplasm Staging | 2 | 2000 | 1967 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2004 | 428 | 0.010 |
Why?
|
Environmental Microbiology | 1 | 2001 | 22 | 0.010 |
Why?
|
Portal System | 1 | 2001 | 13 | 0.010 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 1998 | 237 | 0.010 |
Why?
|
Government Regulation | 1 | 2001 | 49 | 0.010 |
Why?
|
Focal Nodular Hyperplasia | 1 | 2001 | 10 | 0.010 |
Why?
|
Models, Statistical | 1 | 2004 | 575 | 0.010 |
Why?
|
Hamartoma | 1 | 2001 | 34 | 0.010 |
Why?
|
DNA, Bacterial | 1 | 2001 | 237 | 0.010 |
Why?
|
Cytomegalovirus Infections | 1 | 2001 | 146 | 0.010 |
Why?
|
Hemangioma | 1 | 2001 | 63 | 0.010 |
Why?
|
Rats, Inbred Strains | 2 | 1990 | 312 | 0.010 |
Why?
|
Lymphotoxin-alpha | 2 | 1990 | 44 | 0.010 |
Why?
|
Population Surveillance | 1 | 2001 | 216 | 0.010 |
Why?
|
Alanine Transaminase | 2 | 1990 | 74 | 0.010 |
Why?
|
Aspartate Aminotransferases | 2 | 1990 | 73 | 0.010 |
Why?
|
Fibrosis | 1 | 2001 | 211 | 0.010 |
Why?
|
Cysts | 1 | 2001 | 105 | 0.010 |
Why?
|
Feces | 1 | 2001 | 326 | 0.010 |
Why?
|
Risk | 1 | 2001 | 660 | 0.010 |
Why?
|
Cell Division | 1 | 2001 | 695 | 0.010 |
Why?
|
Autoimmune Diseases | 1 | 2001 | 248 | 0.010 |
Why?
|
Radiography, Thoracic | 1 | 2001 | 319 | 0.010 |
Why?
|
Adenoma | 1 | 2001 | 242 | 0.010 |
Why?
|
Plasmapheresis | 1 | 1998 | 25 | 0.010 |
Why?
|
Pregnancy | 2 | 2001 | 2974 | 0.010 |
Why?
|
Pneumonia | 1 | 2000 | 182 | 0.010 |
Why?
|
Drug Resistance, Microbial | 1 | 1998 | 73 | 0.010 |
Why?
|
Gallbladder Diseases | 1 | 1998 | 22 | 0.010 |
Why?
|
Aminosalicylic Acids | 1 | 1998 | 42 | 0.010 |
Why?
|
Pregnancy Complications | 1 | 2001 | 343 | 0.010 |
Why?
|
Lung Diseases | 1 | 2000 | 267 | 0.010 |
Why?
|
Urinary Retention | 1 | 1997 | 42 | 0.010 |
Why?
|
Complement C3 | 1 | 1997 | 58 | 0.010 |
Why?
|
Radiology, Interventional | 1 | 1998 | 68 | 0.010 |
Why?
|
Renal Insufficiency | 1 | 1998 | 102 | 0.010 |
Why?
|
Actuarial Analysis | 1 | 1997 | 66 | 0.010 |
Why?
|
Fluconazole | 1 | 1997 | 10 | 0.010 |
Why?
|
Fibrin | 1 | 1997 | 86 | 0.010 |
Why?
|
Amphotericin B | 1 | 1997 | 34 | 0.010 |
Why?
|
Capillaries | 1 | 1997 | 90 | 0.010 |
Why?
|
Bacteremia | 1 | 1998 | 102 | 0.010 |
Why?
|
Kidney Glomerulus | 1 | 1997 | 120 | 0.010 |
Why?
|
Histocompatibility Testing | 1 | 1996 | 138 | 0.010 |
Why?
|
Treatment Failure | 1 | 1997 | 288 | 0.010 |
Why?
|
Neutrophils | 1 | 1997 | 307 | 0.010 |
Why?
|
Bone Diseases | 1 | 1995 | 54 | 0.010 |
Why?
|
Diabetic Nephropathies | 1 | 1995 | 87 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 1997 | 465 | 0.010 |
Why?
|
Salvage Therapy | 1 | 1996 | 235 | 0.010 |
Why?
|
Safety | 1 | 1995 | 151 | 0.010 |
Why?
|
Glucocorticoids | 1 | 1997 | 358 | 0.010 |
Why?
|
Extremities | 1 | 1995 | 166 | 0.010 |
Why?
|
Immunization, Passive | 1 | 1994 | 72 | 0.010 |
Why?
|
Emergencies | 1 | 1995 | 113 | 0.010 |
Why?
|
Postoperative Care | 1 | 1995 | 224 | 0.010 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 1993 | 29 | 0.010 |
Why?
|
Ischemia | 1 | 1995 | 251 | 0.010 |
Why?
|
Choledochostomy | 1 | 1992 | 8 | 0.010 |
Why?
|
Anastomosis, Roux-en-Y | 1 | 1992 | 26 | 0.010 |
Why?
|
Cholestasis, Intrahepatic | 1 | 1992 | 17 | 0.010 |
Why?
|
Therapeutic Irrigation | 1 | 1992 | 61 | 0.010 |
Why?
|
Dilatation | 1 | 1992 | 48 | 0.010 |
Why?
|
Immune Sera | 1 | 1991 | 52 | 0.010 |
Why?
|
Adenoma, Bile Duct | 1 | 1990 | 4 | 0.010 |
Why?
|
Rats, Inbred BN | 1 | 1990 | 38 | 0.010 |
Why?
|
Immunologic Techniques | 1 | 1990 | 26 | 0.010 |
Why?
|
Transplantation, Isogeneic | 1 | 1990 | 39 | 0.010 |
Why?
|
Raffinose | 1 | 1990 | 24 | 0.010 |
Why?
|
Leukocyte Count | 1 | 1990 | 222 | 0.010 |
Why?
|
Allopurinol | 1 | 1990 | 78 | 0.010 |
Why?
|
Glutathione | 1 | 1990 | 108 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 1995 | 697 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 1991 | 1020 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1989 | 271 | 0.010 |
Why?
|
Analysis of Variance | 1 | 1990 | 901 | 0.000 |
Why?
|
Occupations | 1 | 1988 | 25 | 0.000 |
Why?
|
Adenosine | 1 | 1990 | 237 | 0.000 |
Why?
|
Activities of Daily Living | 1 | 1988 | 207 | 0.000 |
Why?
|
Patient Acceptance of Health Care | 1 | 1988 | 252 | 0.000 |
Why?
|